By Maggie Fick, Bhanvi Satija and Patricia Weiss LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and ...

Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen ...

A symbol of American pharmaceutical innovation for nearly two centuries, Pfizer now faces the challenges of AI adoption and ...

Germany’s new healthcare reform initiative has already led two global drugmakers to slice their planned investments in the ...

Maybe you’ve bought shares of AI company stocks or invested in ETFs focused on AI, technology, or computer science. Or, ...

Pfizer (PFE) CEO and chairman Albert Bourla told Yahoo Finance Executive Editor Brian Sozzi during Yahoo Finance's annual Investconference that the $10 billion acquisition of GLP-1 maker Metsera (MTSR ...

Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon. Even so, Lilly could carve out a niche ...

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity ...

Pfizer CEO Albert Bourla joins 'Squawk Box' to discuss the company's obesity drug pipeline. Got a confidential news tip? We ...

Investors are clearly worried about the safety of Pfizer's dividend, which is reasonable.